Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 596

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

PD-L1 expression and prognostic impact in glioblastoma

Open access
Nduom, Edjah K., Wei, Jun, Yaghi, Nasser K., Huang, Neal, Kong, Ling-Yuan, Gabrusiewicz, Konrad, Ling, Xiaoyang, Zhou, Shouhao, Ivan, Cristina, Chen, Jie Qing, Burks, Jared K., Fuller, Greg N., Calin, George A., Conrad, Charles A., Creasy, Caitlin, Ritthipichai, Krit, Radvanyi, Laszlo, Heimberger, Amy B.·2016·Neuro-Oncology

Abstract

BACKGROUND: Therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) and PD-1/PD-L1 has demonstrated tumor regression in clinical trials, and phase 2 trials are ongoing in glioblastoma (GBM). Previous reports have suggested that responses are more frequent in patients with tumors that express PD-L1; however, this has been disputed. At issue is the validation of PD-L1 biomarker assays and prognostic impact. METHODS: Using immunohistochemical analysis, we measured the incidence of PD-L1 expression in 94 patients with GBM. We categorized our results according to the total number of PD-L1-expressing cells within the GBMs and then validated this finding in ex vivo GBM flow cytometry with further analysis of the T cell populations. We then evaluated the association between PD-L1 expression and median survival time using the protein expression datasets and mRNA from The Cancer Genome Atlas. RESULTS: The median percentage of PD-L1-expressing cells in GBM by cell surface staining is 2.77% (range: 0%-86.6%; n = 92), which is similar to the percentage found by ex vivo flow cytometry. The majority of GBM patients (61%) had tumors with at least 1% or more PD-L1-positive cells, and 38% had at least 5% or greater PD-L1 expression. PD-L1 is commonly expressed on the GBM-infiltrating T cells. Expression of both PD-L1 and PD-1 are negative prognosticators for GBM outcome. CONCLUSIONS: The incidence of PD-L1 expression in GBM patients is frequent but is confined to a minority subpopulation, similar to other malignancies that have been profiled for PD-L1 expression. Higher expression of PD-L1 is correlated with worse outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/nov172

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 596

Metadata

Authors
Nduom, E. K., Wei, J., Yaghi, N. K., Huang, N., Kong, L.-Y., Gabrusiewicz, K., Ling, X., Zhou, S., Ivan, C., Chen, J. Q., Burks, J. K., Fuller, G. N., Calin, G. A., Conrad, C. A., Creasy, C., Ritthipichai, K., Radvanyi, L., & Heimberger, A. B.
Venue
Neuro-Oncology
Published
2015-08-30
Volume
18
Issue
2
Pages
195-205
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W1815157104
Cited by
596
References
8
FWCI
22.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-L1 expression and prognostic impact in glioblastoma. https://app.cochat.ai/papers/10.1093/neuonc/nov172
The paper
Nduom, E. K., Wei, J., Yaghi, N. K., Huang, N., Kong, L.-Y., Gabrusiewicz, K., Ling, X., Zhou, S., Ivan, C., Chen, J. Q., Burks, J. K., Fuller, G. N., Calin, G. A., Conrad, C. A., Creasy, C., Ritthipichai, K., Radvanyi, L., & Heimberger, A. B. (2016). PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/nov172

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.